Abstract：【Objective】 To study the clinical effect of different doses of Apatinib combined with chemotherapy for advanced gastric cancer treatment. 【Methods】 A total of 60 patients with advanced gastric cancer who failed second-line treatment were divided into the observation group (low-dose triple administration of apatinib combined with systemic chemotherapy, 30 cases) and the control group (continuous high dose of apatinib combined with systemic chemotherapy, 30 cases) by random number table method.The short-term effects of chemotherapy were compared between the two groups, and the adverse reactions were recorded during the treatment. The half-year survival rate in two groups were recorded by follow-up. 【Results】 The disease control rate of the observation group after 2 courses of treatment was higher than that of the control group; the difference was statistically significant (P<0.05).There were no significant difference in the severity of adverse reactions such as hypertension, proteinuria, hemorrhage, anemia and leukopenia between the two groups (P>0.05).The severity of gastrointestinal and hand-foot skin reactions in the observation group was significantly less than that in the control group (P<0.05).The half-year survival rate of the observation group was 43.33% (13/30), which was not significantly different from the control group 30.00% (9/30) (P>0.05). 【Conclusion】 Low-dose triple administration of apatinib combined with systemic chemotherapy in the treatment of advanced gastric cancer improves the efficacy of chemotherapy, reduces adverse reactions and has high clinical application value.
肖谜, 王妹兴. 调整剂量阿帕替尼联合三线化疗治疗晚期胃癌的临床疗效[J]. 医学临床研究, 2020, 37(5): 683-685.
XIAO Mi, WANG Mei-xing. Clinical Study of Adjusted doses of Apatinib Combined with Chemotherapy for Advanced Gastric Cancer Treatment. JOURNAL OF CLINICAL RESEARCH, 2020, 37(5): 683-685.
[1] 孙洋,黄晓俊,陈鹭.胃癌相关危险因素的研究进展[J].世界华人消化杂志,2015,23(30):4831-4837. [2] 韩光锋.晚期胃癌的内科治疗现状和进展[J].实用肿瘤杂志,2017,32(6):569-574. [3] 陈希, 苏小琴, 顾红兵,等.阿帕替尼与伊立替康为主的化疗在胃癌三线治疗中的效果比较及安全性研究[J].南通大学学报:医学版,2017,37(6):562-565. [4] Scott LJ. Apatinib: A review in advanced gastric cancer and other advanced cancers[J].Drugs,2018,78(12):1-12. [5] 李元元,刘珏,周庆,等.阿帕替尼致2例严重不良反应分析[J].中国药师,2017,20(11):2037-2038. [6] 中华人民共和国卫生部医政司.胃癌诊疗规范(2011年版)[J].中国医学前沿杂志(电子版), 2012,4(5):62-71. [7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准—RECIST[J].循证医学,2004,4(2):85-90. [8] Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0[J].J Am Acad Dermatol,2012,67(5):1025-1039. [9] 李彤,翟二涛,许丽霞, 等.阿帕替尼通过阻断VEGF通路增强胃癌放疗疗效[J].中国病理生理杂志,2017,33(5):776-781. [10] 秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识[J].临床肿瘤学杂志,2015,20(9):841-847. [11] 田春艳,彭仁,白婷婷,等.阿帕替尼不同起始剂量治疗晚期胃癌不良反应及疗效观察[J].实用肿瘤杂志,2018,33(1):66-69.
2020, Vol. 37 
